Cardiac Biomarker Diagnostic Kits Market Size, Share, Growth, Trends, Revenue, Consumption, Company Analysis and Forecast 2020-2027

CHAPTER 1. Preface
1.1. Definition and Scope
1.2. Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

CHAPTER 2. Assumptions and Research Methodology

CHAPTER 3. Executive Summary : Global Market

CHAPTER 4. Overview
4.1. Introduction
4.1.1. Products Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

CHAPTER 5. Market Key Insights
5.1. Regulatory Scenario by Region/Globally
5.2. Key Mergers & Acquisitions
5.3. Reimbursement Scenario
5.4. Cardiac Diseases Prevalence Rate Globally with Key Countries
5.5. Top 3 players operating in the market space

CHAPTER 6. Global Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Market Value Forecast, by Product, 2016–2026
6.3.1. Troponin Test Kits
6.3.2. CK-MB Test Kits
6.3.3. Myoglobin Test Kits
6.3.4. BNP Test Kit
6.3.5. C-reactive Protein (hsCRP)
6.3.6. Others
6.4. Global Market Attractiveness, by Product

7. Global Market Analysis and Forecast, by Testing
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Market Value Forecast, by Testing, 2016–2026
7.3.1. Laboratory Testing
7.3.2. Pont-of-care Testing
7.4. Global Market Attractiveness, by Testing

8. Global Market Analysis and Forecast, by Disease Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Market Value Forecast, by Disease Indication, 2016–2026
8.3.1. AngiStent Type Pectoris
8.3.2. Myocardial Infraction
8.3.3. Cardiac Heart Failure
8.3.4. Other
8.4. Global Market Attractiveness, by Disease Indication

9. Global Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Global Market Value Forecast, by End-user, 2016–2026
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Diagnostic Laboratory
9.3.4. Others
9.4. Global Market Attractiveness, by End-user

10. Global Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Market Attractiveness, by Region

11. North America Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. North America Market Value Forecast, by Product, 2016–2026
11.2.1. Troponin Test Kits
11.2.2. CK-MB Test Kits
11.2.3. Myoglobin Test Kits
11.2.4. BNP Test Kit
11.2.5. C-reactive Protein (hsCRP)
11.2.6. Others
11.3. North America Market Value Forecast, by Testing, 2016–2026
11.3.1. Laboratory Testing
11.3.2. Pont-of-care Testing
11.4. North America Market Value Forecast, by Disease Indication, 2016–2026
11.4.1. AngiStent Type Pectoris
11.4.2. Myocardial Infraction
11.4.3. Cardiac Heart Failure
11.4.4. Other
11.5. North America Market Value Forecast, by End-user, 2016–2026
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Diagnostic Laboratory
11.5.4. Others
11.6. North America Market Value Forecast, by Country, 2016–2026
11.6.1. U.S.
11.6.2. Canada
11.7. North America Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Testing
11.7.3. By Disease Indication
11.7.4. By End-user
11.7.5. By Country

12. Europe Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Europe Market Value Forecast, by Product, 2016–2026
12.2.1. Troponin Test Kits
12.2.2. CK-MB Test Kits
12.2.3. Myoglobin Test Kits
12.2.4. BNP Test Kit
12.2.5. C-reactive Protein (hsCRP)
12.2.6. Others
12.3. Europe Market Value Forecast, by Testing, 2016–2026
12.3.1. Laboratory Testing
12.3.2. Pont-of-care Testing
12.4. Europe Market Value Forecast, by Disease Indication, 2016–2026
12.4.1. AngiStent Type Pectoris
12.4.2. Myocardial Infraction
12.4.3. Cardiac Heart Failure
12.4.4. Other
12.5. Europe Market Value Forecast, by End-user, 2016–2026
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Diagnostic Laboratory
12.5.4. Others
12.6. Europe Market Value Forecast, by Country/Sub-region, 2016–2026
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Testing
12.7.3. by Disease Indication
12.7.4. by End-user
12.7.5. by Country/Sub-region

13. Asia Pacific Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Asia Pacific Market Value Forecast, by Product, 2016–2026
13.2.1. Troponin Test Kits
13.2.2. CK-MB Test Kits
13.2.3. Myoglobin Test Kits
13.2.4. BNP Test Kit
13.2.5. C-reactive Protein (hsCRP)
13.2.6. Others
13.3. Asia Pacific Market Value Forecast, by Testing, 2016–2026
13.3.1. Laboratory Testing
13.3.2. Pont-of-care Testing
13.4. Asia Pacific Market Value Forecast, by Disease Indication, 2016–2026
13.4.1. AngiStent Type Pectoris
13.4.2. Myocardial Infraction
13.4.3. Cardiac Heart Failure
13.4.4. Other
13.5. Asia Pacific Market Value Forecast, by End-user, 2016–2026
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Diagnostic Laboratory
13.5.4. Others
13.6. Asia Pacific Market Value Forecast, by Country/Sub-region, 2016–2026
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Testing
13.7.3. By Disease Indication
13.7.4. By End-user
13.7.5. By Country/Sub-region

14. Latin America Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Latin America Market Value Forecast, by Product, 2016–2026
14.2.1. Troponin Test Kits
14.2.2. CK-MB Test Kits
14.2.3. Myoglobin Test Kits
14.2.4. BNP Test Kit
14.2.5. C-reactive Protein (hsCRP)
14.2.6. Others
14.3. Latin America Market Value Forecast, by Testing, 2016–2026
14.3.1. Laboratory Testing
14.3.2. Pont-of-care Testing
14.4. Latin America Market Value Forecast, by Disease Indication, 2016–2026
14.4.1. AngiStent Type Pectoris
14.4.2. Myocardial Infraction
14.4.3. Cardiac Heart Failure
14.4.4. Other
14.5. Latin America Market Value Forecast, by End-user, 2016–2026
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Diagnostic Laboratory
14.5.4. Others
14.6. Latin America Market Value Forecast, by Country/Sub-region, 2016–2026
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Testing
14.7.3. By Disease Indication
14.7.4. By End-user
14.7.5. By Country/Sub-region

15. Middle East & Africa Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Middle East & Africa Market Value Forecast, by Product, 2016–2026
15.2.1. Troponin Test Kits
15.2.2. CK-MB Test Kits
15.2.3. Myoglobin Test Kits
15.2.4. BNP Test Kit
15.2.5. C-reactive Protein (hsCRP)
15.2.6. Others
15.3. Middle East & Africa Market Value Forecast, by Testing, 2016–2026
15.3.1. Laboratory Testing
15.3.2. Pont-of-care Testing
15.4. Middle East & Africa Market Value Forecast, by Disease Indication, 2016–2026
15.4.1. AngiStent Type Pectoris
15.4.2. Myocardial Infraction
15.4.3. Cardiac Heart Failure
15.4.4. Other
15.5. Middle East & Africa Market Value Forecast, by End-user, 2016–2026
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Diagnostic Laboratory
15.5.4. Others
15.6. Middle East & Africa Market Value Forecast, by Country/Sub-region, 2016–2026
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Testing
15.7.3. By Disease Indication
15.7.4. By End-user
15.7.5. By Country/Sub-region

16. Competition Landscape
16.1. Market Player – Competition Matrix (by Tier and Size of companies)
16.2. Market Share Analysis by Company (2017)
16.3. Competitive Business Strategies
16.4. Company Profiles
16.4.1. Abbott Laboratories Ltd.
16.4.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.1.2. Business Overview
16.4.1.3. Product Portfolio
16.4.1.4. Financial Overview
16.4.1.5. SWOT Analysis
16.4.2. Hoffmann-La Roche AG
16.4.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.2.2. Business Overview
16.4.2.3. Product Portfolio
16.4.2.4. Financial Overview
16.4.2.5. SWOT Analysis
16.4.3. Bio-Rad Laboratories
16.4.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.3.2. Business Overview
16.4.3.3. Product Portfolio
16.4.3.4. Financial Overview
16.4.3.5. SWOT Analysis
16.4.4. Danaher Corporation
16.4.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.4.2. Business Overview
16.4.4.3. Product Portfolio
16.4.4.4. Financial Overview
16.4.4.5. SWOT Analysis
16.4.5. Seimens Healthineers
16.4.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.5.2. Business Overview
16.4.5.3. Product Portfolio
16.4.5.4. Financial Overview
16.4.5.5. SWOT Analysis
16.4.6. Thermofisher Scientific
16.4.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.6.2. Business Overview
16.4.6.3. Product Portfolio
16.4.6.4. Financial Overview
16.4.6.5. SWOT Analysis
16.4.7. bioMérieux
16.4.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.7.2. Business Overview
16.4.7.3. Product Portfolio
16.4.7.4. Financial Overview
16.4.7.5. SWOT Analysis
16.4.8. Ortho Clinical Diagnostics
16.4.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
16.4.8.2. Business Overview
16.4.8.3. Product Portfolio
16.4.8.4. Financial Overview
16.4.8.5. SWOT Analysis